Where should we focus?
Select the market, indication and buyer where differentiated technology can create a credible first commercial advantage.
Typical outcomeMarket wedge and decision criteria
Founder-led advisory for DeepTech health
Experienced judgment for consequential health-technology decisions.
I advise CEOs, boards and investors navigating the intersection of science, product evidence, strategic partnerships and enterprise value.
Confidential by default · Selective mandates · International scope
The advisory premise
Access to an operator—not another layer of consulting.
The work begins with the decision in front of you. I bring pattern recognition from global pharmaceutical R&D, life-sciences P&L responsibility, transactions and fifteen years of venture building. The objective is a clearer choice, a credible rationale and a path your stakeholders can act on.
Specific executive problems
Four questions that determine whether innovation creates value.
The engagement is anchored to a live business decision—not a generic transformation program.
What must we prove?
Sequence clinical evidence, product claims and stakeholder validation before the company commits scarce time and capital.
Typical outcomeEvidence strategy and 90-day priorities
Who can help us scale?
Shape a partnership proposition that makes the value exchange clear to pharma, MedTech, technology and distribution partners.
Typical outcomePartner thesis and engagement roadmap
How do we make the case?
Turn scientific and technical complexity into a board, investor or diligence narrative that can withstand scrutiny.
Typical outcomeDecision-ready executive narrative
A current point of view
Three forces are converging. Integration is the advantage.
NeuTigers keeps my advisory work grounded in the operating reality of turning advanced algorithms and wearable signals into useful, preventive health applications.
Medical-grade wearables
Continuous physiological data becomes valuable when signal quality, validation and the care pathway are designed together.
Edge-AI inference
On-device intelligence creates new options for latency, privacy, personalization and efficient deployment at global scale.
Preventive healthcare
The commercial opportunity is earlier risk identification and intervention—not simply another stream of health data.
Advisory thesisThe winning strategy is rarely “more AI.” It is a defensible path connecting differentiated IP, credible evidence, a committed buyer and a workflow that changes outcomes.
When I am most useful
The stakes are real, the answer is not obvious, and delay has a cost.
01The technology is strong, but the first commercial wedge is not yet clear.
02Clinical, product and commercial workstreams are moving out of sequence.
03A strategic partner is interested, but the value exchange remains vague.
04The next board, financing or diligence discussion requires sharper logic.
Ways to work together
A tailored mandate, proportionate to the decision.
Scope, cadence and fees are defined after a private fit conversation. Projects can expand into a retainer only when the value is clear.
Strategic Decision Advisory
For a CEO, board or innovation leader facing one consequential choice with a clear decision date.
- Executive diagnostic and decision framing
- Evidence, option and trade-off assessment
- Written recommendation and executive readout
- Action roadmap with owners and next proof points
CEO Advisory Partnership
For leaders who need an experienced, independent thought partner as priorities, risks and stakeholders evolve.
- Recurring CEO working sessions
- Priority access for time-sensitive decisions
- Board, investor and partner preparation
- Review of strategic narratives and work products
Board & Transaction Counsel
For investors and organizations evaluating DeepTech health opportunities, partnerships or portfolios.
- Independent commercial and technology perspective
- Management and diligence question design
- Risk, evidence and value-creation assessment
- Board or investment-committee synthesis
Credibility, made relevant
A career across the full arc of health innovation.
Science, global R&D, portfolio strategy, P&L responsibility, transactions, fundraising and company building.
View LinkedIn profileAventis / Sanofi
Global informatics, drug design and healthcare-solutions leadershipLed work across US, European and APAC research sites; contributed to digital strategy and external-innovation assessment across major therapeutic areas.
Accelrys / BIOVIA
Managing Director, Life SciencesOwned strategy and P&L for a $90M software and services segment and contributed to diligence supporting the reported $750M transaction.
Digital health ventures
CEO, CBO and corporate-development executiveAdvanced venture strategy, fundraising, pharma engagement and commercialization across genomics, real-world data and neurotechnology.
NeuTigers
CEO & FounderBuilding a Princeton-rooted Edge-AI venture focused on wearable-enabled screening and monitoring of chronic and rare diseases.
About Adel
I have worked on both sides of the decision.
Inside the resources and rigor of global pharmaceutical R&D—and inside the uncertainty of building DeepTech health ventures from IP, evidence and partnership conviction.
Today, as CEO and Founder of NeuTigers, I remain close to the practical questions facing innovators: what to build, what to prove, whom to partner with and how to create a credible path to scale.
Begin with the decision
What must your organization decide in the next 90 days?
Send five lines: your organization, the decision, why it matters now, what changes if you get it right and when action is required.
Request a private conversation No pitch deck required · No obligation · Confidential by default